1,188 results on '"Brunner, Hermine"'
Search Results
102. Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis
103. 503 Developing a standardized steroid dosing regimen in pediatric proliferative lupus nephritis
104. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial
105. 2021 DORIS definition of remission in SLE: final recommendations from an international task force
106. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab
107. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
108. Randomized, Double-Blind, Dose-Escalation Trial of Triptorelin for Ovary Protection in Childhood-Onset Systemic Lupus Erythematosus
109. Catch-Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: Results From a Phase III Trial
110. Half-Life and Safety of Canakinumab in Pediatric Patients: Comment on the Article by Ilowite et al
111. Developing outcome measures for paediatric rheumatic diseases
112. Proceedings from the 4th NextGen Therapies for SJIA and MAS virtual symposium held February 13–14, 2022.
113. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.
114. 14 - Therapeutics: Biologics and Small Molecules
115. Corrigendum to “Successful Urine Multiplex Bead Assay to Measure Lupus Nephritis Activity” Kidney Int. Rep. 2021;6:1949-1960.
116. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
117. International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis
118. The Evolution of Population Pharmacokinetic Models to Describe the Enterohepatic Recycling of Mycophenolic Acid in Solid Organ Transplantation and Autoimmune Disease
119. Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells
120. A156: Pharmacokinetics and Pharmacogenetics of Mycophenolic Acid and Response to Therapy in Childhood-Onset Systemic Lupus Erythematosus
121. A148: A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results
122. Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus
123. Biomarkers for renal disease in childhood
124. The impact and implications of neuropsychiatric systemic lupus erythematosus in adolescents
125. Efficacy and safety of tocilizumab for polyarticular-course juvenile idiopathic arthritis in the open-label two-year extension of a phase III trial
126. Cross-cultural adaptation and initial validation of the Brazilian-Portuguese version of the pediatric automated neuropsychological assessment metrics.
127. Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis
128. Identification of a urinary proteomic signature for lupus nephritis in children
129. School Support and Functioning for Children with Juvenile Rheumatic Diseases
130. Pain, Fatigue, Family Functioning, and Attitude Toward Illness in Children with Juvenile Rheumatic Diseases
131. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
132. 2021 DORIS definition of remission in SLE: final recommendations from an international task force.
133. 2021 DORIS definition of remission in SLE:Final recommendations from an international task force
134. Understanding the biology and use of anti-TNF agents in JIA – interim results
135. Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
136. Developing consensus treatment plans for proliferative lupus nephritis in childhood-onset systemic lupus erythematous
137. Use of immunosuppressive medications and prevalence of disability among patients with pediatric systemic lupus erythematosus: initial analysis of the CARRAnet registry
138. Biologics in paediatric rheumatic diseases
139. Subcutaneous Abatacept in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis
140. Achieving consensus on quality indicators (QI) for pediatric Systemic Lupus Erythematosus (pSLE)
141. Defining clinical remission and clinically inactive disease in juvenile systemic lupus erythematosus (jSLE)
142. Performance of the New 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in Children and Young Adults
143. Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis
144. OPINION: The landscape of comparative effectiveness research in rheumatology
145. Characterization Of Changes In Gene Expression and Inflammatory Proteins In Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy.: 1692
146. Pharmacokinetics and pharmacodynamics of long-term tocilizumab therapy in polyarticular juvenile idiopathic arthritis.: 173.
147. Pharmacokinetics and pharmacodynamics of long-term tocilizumab therapy in patients with systemic juvenile idiopathic arthritis.: 172.
148. Brain Morphometric Changes Associated With Childhood-Onset Systemic Lupus Erythematosus and Neurocognitive Deficit
149. Neuroinflammation and Pediatric Lupus
150. Contributors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.